80 Toxicity and Quality of Life Results from a Randomized Phase II Trial of HDR Monotherapy for Low and Intermediate-Risk Prostate Cancer. (October 2019) - Hasan, Yaser; Loblaw, Andrew; Chung, Hans; McGuffin, Merrylee; Tseng, Chia-Lin; Mendez, Lucas; Ravi, Ananth; Zhang, Liying; Mamedov, Alexandre; Morton, Gerard